Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting
The Effectiveness of Preoperative Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting After Total Knee Replacement in Hemophilia A
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yuelan Wang
- Phone Number: 15953105780
- Email: wyldgf@163.com
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Shandong Provincial Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The patients with hemophilia A undergoing unilateral total knee arthroplasty.
- The age of the patients ranged from 18 to 70 years.
- American Society of Anesthesiologists is graded as I~III
- No history of mental illness
- No history of antiemetic and anticholinergic drugs.
- No history of serious gastrointestinal diseases.
Exclusion Criteria:
- Patients who have received long-term steroid treatment
- Patients who need more than 2.5 mg neostigmine to reverse muscle relaxants
- Patients with previous malignant tumor, malabsorption, morbid obesity, hypogonadism, thyroid and parathyroid diseases and autoimmune diseases.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of PONV in patients with hemophilia A receiving general anesthesia orders for knee arthroplasty
Time Frame: up to 24 hours after surgery
|
PONV was defined as the onset of nausea or vomiting within 24 hours after surgery
|
up to 24 hours after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The amount of postoperative antiemetics
Time Frame: up to 24 hours after surgery
|
antiemetics includes ondansetron, metoclopramide, dexamethasone
|
up to 24 hours after surgery
|
|
VAS score after returning to the ward
Time Frame: immediately after returning to the ward
|
postoperative pain can be evaluated using the visual analogue scale (0-10 score, 0: no pain, 10: worst imaginable pain).
|
immediately after returning to the ward
|
|
Usage of PCIA
Time Frame: up to 24 hours after surgery
|
the use of postoperative patient controlled intravenous analgesia
|
up to 24 hours after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yuelan Wang, China, Shandong Qianfoshan Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- neutrophil-to-lymphocyte ratio
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.